Researchers develop early Alzheimers diagnostic method using tau protein analysis Advancements in Alzheimers detection reveal ...

Enter SynPull, a new synaptosome imaging method developed by David Klenerman, John Danial, and colleagues at the University of Cambridge, England. SynPull combines single-molecule pull-down of ...

Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing ...

Discover how UHT high-protein beverages are evolving with advanced emulsifier-stabilizer blends, enhancing texture, stability ...

The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...

Torrey Pines Investment, a specialty life-science investment company based in San Diego, CA, and Oost NL, a regional development agency supporting innovation-driven companies, announced the pre-seed ...

Due to proteostasis stress induced by aging or disease, misfolded proteins can form toxic intermediate species of aggregates and eventually mature into less toxic inclusion bodies (IBs). Here, using a ...

Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...

A complementary drug to combat Alzheimer’s disease could target a specific part of the nerve cell protein tau. This is the ...

NKGen Biotech (NKGN) announced the publication of results from the Company’s initial dose escalation Phase 1 clinical trial of troculeucel, an ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...